Who
Elaine O'Hara
EVP, Chief Strategy Officer
Company insider
Files Form 4 as: EVP, Chief Strategy Officer, Novavax.
In numbers
- Trades disclosed
- 38
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2023
- Last trade
- 3 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —56,334 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $213K22,429 at $9.49 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,334 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,334 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —56,334 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $213K22,429 at $9.49 | filing |
| 2 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,500 at $0.00 | filing |
| 2 Mar 2026filed 9 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,500 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.6M177,500 at $9.09 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —118,000 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $1.6M177,500 at $9.09 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —19,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $55K5,375 at $10.14 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code F | $111K10,969 at $10.14 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
News
Elaine O'Hara detectives recall first impressions of Graham Dwyer during murder investigationirishmirror.ie · 27 Sep 2026
1 headline in the last 90 days name Elaine O'Hara; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.